Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Eliem Therapeutics, Inc. (ELYM)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Mar-05-23 | Dec-31-22 | Dec-05-22 | Sep-30-22 | Sep-05-22 | Jun-30-22 |
| | 10-Q | 10-Q | 8-K | 10-K | 8-K | 10-Q | 8-K | 10-Q |
| Revenues | 100.0% | 100.0% | 100.0% | | 100.0% | | 100.0% | |
| Cost of goods sold | 0.0% | 0.0% | 200.0% | | 193.9% | | 205.4% | |
| Gross profit | 100.0% | 100.0% | -100.0% | | -93.9% | | -105.4% | |
| Research and development | 51.8% | 18.4% | | | | | | |
| General and administrative | 42.5% | 56.9% | 309.8% | | 93.9% | | 105.4% | |
| EBIT | -88.8% | -53.5% | -409.8% | | -193.9% | | -205.4% | |
| Pre-tax income | -73.4% | -71.6% | 0.0% | | -157.5% | | -227.4% | |
| Income taxes | 0.0% | 0.0% | 0.0% | | 0.0% | | 0.0% | |
| Net income | -73.4% | -71.6% | 0.0% | | -0.2% | | -0.2% | |
|